Search this site

Coming Soon.

Neurofibromatosis Type 1, Type 2, and Schwannomatosis Q. What is Neurofibromatosis? Neurofibromatosis refers to a group of autosomal dominant neurocutaneous disorders characterized by the formation of nerve sheath tumors, skin pigmentation abnormalities, and systemic manifestations involving multiple organ systems. The three major recognized forms are Neurofibromatosis Type 1 (NF1), Neurofibromatosis Type 2 (NF2), and Schwannomatosis, all part of the neurofibromatosis-schwannomatosis spectrum. Neurofibromatosis Type 1 (NF1) Q. What is the genetic basis of NF1? NF1 results from mutations in the NF1 gene on chromosome 17q11.2, which encodes neurofibromin, a tumor suppressor protein that negatively regulates RAS signaling. Loss of neurofibromin leads to excessive RAS/MAPK pathway activation and uncontrolled Schwann cell proliferation. Q. What is the inheritance pattern? NF1 is autosomal dominant with variable expressivity and complete penetrance by adulthood. Around 50% of cases arise from de novo mutations. Q. What are the updated 2021 International Diagnostic Criteria for Neurofibromatosis Type 1 (NF1)? Diagnosis requires two or more of the following: 1. Six or more café-au-lait macules (>5 mm prepubertal, >15 mm postpubertal). 2. Two or more neurofibromas of any type, or one plexiform neurofibroma. 3. Axillary or inguinal freckling (Crowe sign). 4. Optic pathway glioma. 5. Two or more Lisch nodules (iris hamartomas), OR two or more choroidal abnormalities (bright patch lesions identified by near-infrared reflectance imaging / optical coherence tomography). 6. Distinctive osseous lesion such as sphenoid wing dysplasia, anterolateral bowing of the tibia, or pseudarthrosis of a long bone. 7. A heterozygous pathogenic NF1 gene variant with a variant allele fraction of 50% in normal tissue. 8. A parent who meets the diagnostic criteria for NF1 specified above. (Only a biological parent who officially meets the diagnostic criteria qualifies as a positive family history. Siblings and children no longer satisfy this criterion on their own, even if they have confirmed cases of NF1.) Q. What are the additional supportive (nonessential) features of NF1? Macrocephaly, short stature, and learning disabilities or ADHD. Seizures, developmental delay, or autism spectrum traits. Scoliosis, vertebral scalloping, long bone bowing, and tibial dysplasia. Vascular lesions (e.g., renal artery stenosis, moyamoya-like disease). Endocrine abnormalities, including precocious puberty (optic-hypothalamic glioma). Pheochromocytoma, GISTs, glomus tumors, and juvenile xanthogranulomas. Choroidal hamartomas visible on near-infrared OCT. Elephantiasis neuromatosa from plexiform neurofibroma overgrowth. Q. What are the clinical features of NF1? Cutaneous: café-au-lait macules, axillary/inguinal freckles, dermal and plexiform neurofibromas. Ophthalmic: Lisch nodules, optic pathway glioma. Neurologic: learning disability, ADHD, seizures, headaches. Skeletal: scoliosis, bone dysplasia. Tumors: MPNST, astrocytoma, pheochromocytoma. Q. What are the radiologic findings? MRI brain may show optic pathway glioma and T2 hyperintense white matter lesions (“unidentified bright objects”). Plexiform neurofibromas appear as T2 target sign lesions. Q. How is NF1 managed? Observation for asymptomatic lesions. Surgical excision for symptomatic or disfiguring neurofibromas. Optic gliomas: observe unless progressive visual loss. When treatment is required for progressive vision loss or imaging advancement, chemotherapy (e.g., carboplatin/vincristine or BRAF/MEK inhibitors) is first-line; radiation is strictly avoided due to the high risk of secondary malignancies and moyamoya syndrome. Screening: annual BP, ophthalmology, and neuro exam; MRI only if symptomatic. MPNST suspicion: rapid growth, pain, or heterogeneity on MRI → biopsy. Q. What is the prognosis? Most live normal lifespans; risk of malignant transformation (MPNST) and vascular complications determine prognosis. Neurofibromatosis Type 2 (NF2) Q. What is the genetic basis of NF2? NF2 is caused by mutations in the NF2 gene on chromosome 22q12, encoding merlin (schwannomin), a tumor suppressor that regulates cell–cell contact inhibition. Loss of merlin leads to Schwann cell overgrowth and meningeal proliferation. Q. What is the inheritance pattern? NF2 is autosomal dominant with variable expression and near-complete penetrance by age 60. Around 50% are de novo mutations, and one-third of those are mosaic. Q. What are the diagnostic criteria for NF2-related schwannomatosis (updated 2022)? Diagnosis can be made by: 1. Bilateral vestibular schwannomas, or 2. A first-degree relative with NF2-related schwannomatosis plus either - unilateral vestibular schwannoma, or - any two of: meningioma, schwannoma, glioma, neurofibroma, or juvenile cataract. 3. NF2 pathogenic variant in blood or tumor, with compatible clinical features. Q. What are supportive clinical features of NF2? Bilateral vestibular schwannomas (pathognomonic). Multiple meningiomas (intracranial and spinal). Spinal ependymomas and schwannomas. Ocular: posterior subcapsular cataract, epiretinal membranes, retinal hamartomas. Cutaneous: plaque-like or subcutaneous schwannomas (no café-au-lait spots). Cranial neuropathies and hearing loss as early symptoms. Family history of early-onset hearing loss or CNS tumors. Q. What is the typical age of presentation? Adolescence or early adulthood, though pediatric onset may occur in mosaic NF2. Q. What are the imaging findings? MRI Brain/IAC: bilateral vestibular schwannomas, multiple meningiomas. MRI spine: intradural extramedullary schwannomas, ependymomas, or meningiomas. Q. How is NF2 managed? MRI surveillance (brain and spine every 12–24 months). Microsurgery or radiosurgery for symptomatic tumors. Bevacizumab for progressive vestibular schwannomas to reduce growth and improve hearing. Rehabilitation with cochlear or brainstem implants for hearing loss. Genetic counseling for family. Q. What is the prognosis? Progressive and multisystemic; median life expectancy around 60 years. Morbidity arises from bilateral hearing loss and brainstem compression. Schwannomatosis Q. What is schwannomatosis? Schwannomatosis is a rare tumor predisposition syndrome characterized by multiple non-vestibular schwannomas without bilateral vestibular schwannomas. It is now considered part of the NF2-related schwannomatosis spectrum. Q. What is the genetic basis? Three defined molecular subtypes: 1. NF2-related schwannomatosis – NF2 gene mutation (chromosome 22q12). 2. SMARCB1-related schwannomatosis – SMARCB1 mutation (chromosome 22q11.23). 3. LZTR1-related schwannomatosis – LZTR1 mutation (chromosome 22q11.23). Tumorigenesis follows a four-hit, three-step model: biallelic loss of both NF2 and one modifier gene (SMARCB1 or LZTR1) in the same cell. Q. What is the inheritance pattern? Autosomal dominant with incomplete penetrance and variable expressivity. Many cases are sporadic. Q. What are the diagnostic criteria (2022 update)? Clinical diagnosis: - Two or more non-intradermal schwannomas confirmed histologically. - No bilateral vestibular schwannomas on MRI. - No constitutional NF2 mutation or first-degree relative with NF2. Molecular diagnosis: - Pathogenic variant in SMARCB1, LZTR1, or NF2, in germline or mosaic form, without bilateral vestibular involvement. Q. What are the clinical features? Chronic or paroxysmal pain (hallmark symptom). Palpable nerve masses along peripheral or spinal nerves. No vestibular or hearing symptoms. Minimal skin lesions, no café-au-lait spots or Lisch nodules. May have mononeuropathies or focal weakness due to nerve compression. Q. What are the radiological features? MRI: multiple enhancing schwannomas along peripheral or spinal nerves, no vestibular schwannomas. Diffusion and contrast help differentiate from meningiomas or neurofibromas. Q. What are the histopathological findings? Typical schwannoma pattern: - Antoni A and Antoni B areas. - Verocay bodies in Antoni A. - Strong S-100 positivity. - No entrapped axons (unlike neurofibroma). Q. What are the differences among genetic subtypes? SMARCB1-related: early onset, spinal schwannomas, occasional meningiomas. LZTR1-related: peripheral nerve tumors, occasional unilateral vestibular schwannoma. NF2-related: mosaic or milder NF2 phenotype. Q. How is schwannomatosis managed? Surgical resection of symptomatic schwannomas. Pain control with neuropathic agents and nerve blocks. MRI surveillance every 2–3 years. Genetic counseling for family. No established drug therapy; bevacizumab is ineffective except in NF2-related cases. Q. What is the prognosis? Excellent life expectancy; main morbidity is chronic neuropathic pain and recurrent surgeries. Histologic Discussion: Schwannoma vs Neurofibroma Q. How do schwannoma and neurofibroma differ? Schwannoma: encapsulated, eccentric to nerve, purely Schwann cells, Antoni A/B areas, Verocay bodies, strong S-100, no axons, enucleable, rare malignancy. Neurofibroma: unencapsulated, intraneural, mixed cell types with axons inside, patchy S-100, CD34 positive stroma, “shredded carrot” collagen, plexiform type has MPNST risk. Target sign on MRI typical for neurofibroma; heterogeneous appearance for schwannoma. Q. What are Antoni A and Antoni B areas, and Verocay bodies? Antoni A areas are hypercellular and organized with nuclear palisading. Antoni B areas are hypocellular, myxoid, and loosely arranged. Verocay bodies are rows of palisaded nuclei separated by acellular eosinophilic zones of Schwann cell processes, pathognomonic for schwannoma. Q. What is segmental or mosaic NF? A postzygotic mutation causing localized disease limited to one body segment; germline mosaicism can still transmit generalized NF to offspring. Q. What is plexiform neurofibroma and why is it significant? Pathognomonic of NF1, involving multiple fascicles (“bag of worms”). Carries 10–15% risk of malignant transformation to MPNST. Q. What is MPNST? A high-grade sarcoma arising from plexiform neurofibroma or peripheral nerve sheath, characterized by pain, rapid growth, and heterogeneous MRI appearance. Genetic mechanisms of tumorigenesis: Both NF1 and NF2 follow the two-hit tumor suppressor model; loss of both alleles (somatic and germline) causes tumor formation. NF1: RAS pathway dysregulation. NF2: loss of contact inhibition via merlin deficiency. Follow-up protocols: NF1 – annual BP, neuro and eye exams, MRI if symptomatic. NF2 – MRI brain/IAC annually, spine every 2–3 years, audiology yearly. Schwannomatosis – MRI every 2–3 years, pain and nerve function monitoring. Final recall summary: NF1 = Peripheral + Pigmentary. NF2 = Central + Vestibular. Schwannomatosis = Multiple Painful Schwannomas, No Vestibular Involvement.

Petrosal Approach Revisited | Part 2 Refining anatomical concepts and operative strategy for accessing petroclival lesions with focus on petrous bone landmarks, cranial nerve relationships, and skull base exposure. Sylvian Fissure Splitting Guide Master Sylvian fissure splitting with a clear, step-by-step approach. This video breaks down microsurgical anatomy, safe dissection planes, arachnoid opening techniques, and key operative landmarks. Case-Based Approach to Frontal Lesions | Part 2 Discussion on bifrontal and subfrontal approaches, using olfactory groove meningioma as the key example. Topics include imaging, tumor extension, surgical corridor planning, and risk anticipation. Case-Based Approach to Frontal Lesions | Part 1 Frontal lesions can present with subtle cognitive, behavioral, motor, language, seizure, or executive function changes. This session simplifies the diagnostic reasoning process and highlights surgical considerations in real-world practice. Cranial Neurosurgical Approaches Pterional Craniotomy Learn the key surface landmarks, burr hole placement, bone flap design, sphenoid wing drilling, and surgical principles that make this approach essential for aneurysm surgery, skull base tumors, and transsylvian procedures. Petrous Bone Surgical Anatomy Essential anatomical landmarks for mastering skull base approaches, including anterior, posterior, and combined petrosal techniques. Includes guide for safe drilling and corridor development. Petrosal Approach | Part 1 Comprehensive guide to core anatomical concepts, surgical corridors, and operative strategy for one of the most versatile yet technically demanding skull base approaches.

Hemangioblastomas In this session of The Neurosurgical Case Room, we discuss the radiologic hallmarks, clinical presentation, vascular considerations, and decision-making in hemangioblastoma. In this session of The Neurosurgical Case Room, we focus on the management and operative strategy for hemangioblastoma, one of the most vascular tumors encountered in posterior fossa surgery. The discussion centers on surgical planning, approach selection, and the principle of en bloc resection to prevent uncontrolled bleeding. Key nuances such as preservation of venous drainage, sequential control of arterial feeders, and avoidance of internal debulking are emphasized. We also address decision-making in cerebellar lesions and the clinical context of Von Hippel–Lindau disease.

Excellence Without Borders. The Neurosurgical Mindset. A global platform for neurosurgical thinking, training, and conversations. Explore our Clinical Library Global Neurosurgery Conversations The Neurosurgical Case Room A Space for the Neurosurgical Mindset The Neurosurgical Case Room is an initiative by two Pakistani neurosurgeons, Dr. Kanwal Ali and Dr. Etizaz Ahmed, aimed at building a neurosurgical community that transcends geography and resources. In just eight months, TNCR has grown to a WhatsApp community of 780+ neurosurgeons and residents across 65+ countries, alongside 90+ interactive sessions and more than 39,000 cumulative YouTube views since January 2026. Global Neurosurgery Conversations A flagship series featuring neurosurgeons from across the world, exploring training, surgical philosophy, and the mindset behind excellence. View All Conversations → A growing collection of interactive Zoom-based video sessions designed primarily for neurosurgical residents, combining focused teaching and case-based discussion. Each session aims to cover a specific topic comprehensively, from core concepts to clinical application, providing structured, practical learning throughout residency. Cranial Core neurosurgical principles and operative thinking. Clinical Library Spine Degenerative, trauma, and surgical decision-making. Explore Clinical Library Anatomy Approaches, anatomy, and high-stakes judgment. TNCR Rapid Review TNCR Review Notes are concise, exam-focused revision notes written primarily for FCPS and MS Neurosurgery exit examination candidates. They are also designed to support neurosurgery residents at all stages of training who need a structured resource for quick review and reinforcement of key concepts. These notes are intended as a supplement to, not a replacement for, standard neurosurgical textbooks and primary literature. The Team Built by neurosurgeons. Supported by a growing global network. Meet the Team Enter the Case Room Get early access to conversations, curated clinical content, and upcoming releases. Email Address* Join Now

Neurofibromatosis Type 1, Type 2, and Schwannomatosis Q. What is Neurofibromatosis? Neurofibromatosis refers to a group of autosomal dominant neurocutaneous disorders characterized by the formation of nerve sheath tumors, skin pigmentation abnormalities, and systemic manifestations involving multiple organ systems. The three major recognized forms are Neurofibromatosis Type 1 (NF1), Neurofibromatosis Type 2 (NF2), and Schwannomatosis, all part of the neurofibromatosis-schwannomatosis spectrum. Neurofibromatosis Type 1 (NF1) Q. What is the genetic basis of NF1? NF1 results from mutations in the NF1 gene on chromosome 17q11.2, which encodes neurofibromin, a tumor suppressor protein that negatively regulates RAS signaling. Loss of neurofibromin leads to excessive RAS/MAPK pathway activation and uncontrolled Schwann cell proliferation. Q. What is the inheritance pattern? NF1 is autosomal dominant with variable expressivity and complete penetrance by adulthood. Around 50% of cases arise from de novo mutations. Q. What are the updated 2021 International Diagnostic Criteria for Neurofibromatosis Type 1 (NF1)? Diagnosis requires two or more of the following: 1. Six or more café-au-lait macules (>5 mm prepubertal, >15 mm postpubertal). 2. Two or more neurofibromas of any type, or one plexiform neurofibroma. 3. Axillary or inguinal freckling (Crowe sign). 4. Optic pathway glioma. 5. Two or more Lisch nodules (iris hamartomas), OR two or more choroidal abnormalities (bright patch lesions identified by near-infrared reflectance imaging / optical coherence tomography). 6. Distinctive osseous lesion such as sphenoid wing dysplasia, anterolateral bowing of the tibia, or pseudarthrosis of a long bone. 7. A heterozygous pathogenic NF1 gene variant with a variant allele fraction of 50% in normal tissue. 8. A parent who meets the diagnostic criteria for NF1 specified above. (Only a biological parent who officially meets the diagnostic criteria qualifies as a positive family history. Siblings and children no longer satisfy this criterion on their own, even if they have confirmed cases of NF1.) Q. What are the additional supportive (nonessential) features of NF1? Macrocephaly, short stature, and learning disabilities or ADHD. Seizures, developmental delay, or autism spectrum traits. Scoliosis, vertebral scalloping, long bone bowing, and tibial dysplasia. Vascular lesions (e.g., renal artery stenosis, moyamoya-like disease). Endocrine abnormalities, including precocious puberty (optic-hypothalamic glioma). Pheochromocytoma, GISTs, glomus tumors, and juvenile xanthogranulomas. Choroidal hamartomas visible on near-infrared OCT. Elephantiasis neuromatosa from plexiform neurofibroma overgrowth. Q. What are the clinical features of NF1? Cutaneous: café-au-lait macules, axillary/inguinal freckles, dermal and plexiform neurofibromas. Ophthalmic: Lisch nodules, optic pathway glioma. Neurologic: learning disability, ADHD, seizures, headaches. Skeletal: scoliosis, bone dysplasia. Tumors: MPNST, astrocytoma, pheochromocytoma. Q. What are the radiologic findings? MRI brain may show optic pathway glioma and T2 hyperintense white matter lesions (“unidentified bright objects”). Plexiform neurofibromas appear as T2 target sign lesions. Q. How is NF1 managed? Observation for asymptomatic lesions. Surgical excision for symptomatic or disfiguring neurofibromas. Optic gliomas: observe unless progressive visual loss. When treatment is required for progressive vision loss or imaging advancement, chemotherapy (e.g., carboplatin/vincristine or BRAF/MEK inhibitors) is first-line; radiation is strictly avoided due to the high risk of secondary malignancies and moyamoya syndrome. Screening: annual BP, ophthalmology, and neuro exam; MRI only if symptomatic. MPNST suspicion: rapid growth, pain, or heterogeneity on MRI → biopsy. Q. What is the prognosis? Most live normal lifespans; risk of malignant transformation (MPNST) and vascular complications determine prognosis. Neurofibromatosis Type 2 (NF2) Q. What is the genetic basis of NF2? NF2 is caused by mutations in the NF2 gene on chromosome 22q12, encoding merlin (schwannomin), a tumor suppressor that regulates cell–cell contact inhibition. Loss of merlin leads to Schwann cell overgrowth and meningeal proliferation. Q. What is the inheritance pattern? NF2 is autosomal dominant with variable expression and near-complete penetrance by age 60. Around 50% are de novo mutations, and one-third of those are mosaic. Q. What are the diagnostic criteria for NF2-related schwannomatosis (updated 2022)? Diagnosis can be made by: 1. Bilateral vestibular schwannomas, or 2. A first-degree relative with NF2-related schwannomatosis plus either - unilateral vestibular schwannoma, or - any two of: meningioma, schwannoma, glioma, neurofibroma, or juvenile cataract. 3. NF2 pathogenic variant in blood or tumor, with compatible clinical features. Q. What are supportive clinical features of NF2? Bilateral vestibular schwannomas (pathognomonic). Multiple meningiomas (intracranial and spinal). Spinal ependymomas and schwannomas. Ocular: posterior subcapsular cataract, epiretinal membranes, retinal hamartomas. Cutaneous: plaque-like or subcutaneous schwannomas (no café-au-lait spots). Cranial neuropathies and hearing loss as early symptoms. Family history of early-onset hearing loss or CNS tumors. Q. What is the typical age of presentation? Adolescence or early adulthood, though pediatric onset may occur in mosaic NF2. Q. What are the imaging findings? MRI Brain/IAC: bilateral vestibular schwannomas, multiple meningiomas. MRI spine: intradural extramedullary schwannomas, ependymomas, or meningiomas. Q. How is NF2 managed? MRI surveillance (brain and spine every 12–24 months). Microsurgery or radiosurgery for symptomatic tumors. Bevacizumab for progressive vestibular schwannomas to reduce growth and improve hearing. Rehabilitation with cochlear or brainstem implants for hearing loss. Genetic counseling for family. Q. What is the prognosis? Progressive and multisystemic; median life expectancy around 60 years. Morbidity arises from bilateral hearing loss and brainstem compression. Schwannomatosis Q. What is schwannomatosis? Schwannomatosis is a rare tumor predisposition syndrome characterized by multiple non-vestibular schwannomas without bilateral vestibular schwannomas. It is now considered part of the NF2-related schwannomatosis spectrum. Q. What is the genetic basis? Three defined molecular subtypes: 1. NF2-related schwannomatosis – NF2 gene mutation (chromosome 22q12). 2. SMARCB1-related schwannomatosis – SMARCB1 mutation (chromosome 22q11.23). 3. LZTR1-related schwannomatosis – LZTR1 mutation (chromosome 22q11.23). Tumorigenesis follows a four-hit, three-step model: biallelic loss of both NF2 and one modifier gene (SMARCB1 or LZTR1) in the same cell. Q. What is the inheritance pattern? Autosomal dominant with incomplete penetrance and variable expressivity. Many cases are sporadic. Q. What are the diagnostic criteria (2022 update)? Clinical diagnosis: - Two or more non-intradermal schwannomas confirmed histologically. - No bilateral vestibular schwannomas on MRI. - No constitutional NF2 mutation or first-degree relative with NF2. Molecular diagnosis: - Pathogenic variant in SMARCB1, LZTR1, or NF2, in germline or mosaic form, without bilateral vestibular involvement. Q. What are the clinical features? Chronic or paroxysmal pain (hallmark symptom). Palpable nerve masses along peripheral or spinal nerves. No vestibular or hearing symptoms. Minimal skin lesions, no café-au-lait spots or Lisch nodules. May have mononeuropathies or focal weakness due to nerve compression. Q. What are the radiological features? MRI: multiple enhancing schwannomas along peripheral or spinal nerves, no vestibular schwannomas. Diffusion and contrast help differentiate from meningiomas or neurofibromas. Q. What are the histopathological findings? Typical schwannoma pattern: - Antoni A and Antoni B areas. - Verocay bodies in Antoni A. - Strong S-100 positivity. - No entrapped axons (unlike neurofibroma). Q. What are the differences among genetic subtypes? SMARCB1-related: early onset, spinal schwannomas, occasional meningiomas. LZTR1-related: peripheral nerve tumors, occasional unilateral vestibular schwannoma. NF2-related: mosaic or milder NF2 phenotype. Q. How is schwannomatosis managed? Surgical resection of symptomatic schwannomas. Pain control with neuropathic agents and nerve blocks. MRI surveillance every 2–3 years. Genetic counseling for family. No established drug therapy; bevacizumab is ineffective except in NF2-related cases. Q. What is the prognosis? Excellent life expectancy; main morbidity is chronic neuropathic pain and recurrent surgeries. Histologic Discussion: Schwannoma vs Neurofibroma Q. How do schwannoma and neurofibroma differ? Schwannoma: encapsulated, eccentric to nerve, purely Schwann cells, Antoni A/B areas, Verocay bodies, strong S-100, no axons, enucleable, rare malignancy. Neurofibroma: unencapsulated, intraneural, mixed cell types with axons inside, patchy S-100, CD34 positive stroma, “shredded carrot” collagen, plexiform type has MPNST risk. Target sign on MRI typical for neurofibroma; heterogeneous appearance for schwannoma. Q. What are Antoni A and Antoni B areas, and Verocay bodies? Antoni A areas are hypercellular and organized with nuclear palisading. Antoni B areas are hypocellular, myxoid, and loosely arranged. Verocay bodies are rows of palisaded nuclei separated by acellular eosinophilic zones of Schwann cell processes, pathognomonic for schwannoma. Q. What is segmental or mosaic NF? A postzygotic mutation causing localized disease limited to one body segment; germline mosaicism can still transmit generalized NF to offspring. Q. What is plexiform neurofibroma and why is it significant? Pathognomonic of NF1, involving multiple fascicles (“bag of worms”). Carries 10–15% risk of malignant transformation to MPNST. Q. What is MPNST? A high-grade sarcoma arising from plexiform neurofibroma or peripheral nerve sheath, characterized by pain, rapid growth, and heterogeneous MRI appearance. Genetic mechanisms of tumorigenesis: Both NF1 and NF2 follow the two-hit tumor suppressor model; loss of both alleles (somatic and germline) causes tumor formation. NF1: RAS pathway dysregulation. NF2: loss of contact inhibition via merlin deficiency. Follow-up protocols: NF1 – annual BP, neuro and eye exams, MRI if symptomatic. NF2 – MRI brain/IAC annually, spine every 2–3 years, audiology yearly. Schwannomatosis – MRI every 2–3 years, pain and nerve function monitoring. Final recall summary: NF1 = Peripheral + Pigmentary. NF2 = Central + Vestibular. Schwannomatosis = Multiple Painful Schwannomas, No Vestibular Involvement.

Hydrocephalus Hydrocephalus is defined as an abnormal accumulation of cerebrospinal fluid (CSF) within the ventricular system of the brain, resulting from obstruction of CSF flow, impairment of CSF absorption, or, rarely, CSF overproduction. The pathophysiology reflects either proximal stagnation of CSF, failure of reabsorption, or mechanical blockage anywhere between the ventricular system and the arachnoid granulations. Q. What is the epidemiology of hydrocephalus? Hydrocephalus affects approximately 1–1.5% of the general population. Congenital hydrocephalus has an incidence of 0.9–1.8 per 1000 births, with an overall reported range from 0.2–3.5 per 1000. It may be detected antenatally, at birth, or in the early months of life. Hydrocephalus occurs across all age groups, with congenital and infantile forms being the most common early-life presentations, whereas normal-pressure hydrocephalus predominates in older adults. Q. How do you classify hydrocephalus? Hydrocephalus can be classified broadly into functional, etiologic, pressure-based, and morphologic categories. A. Functional Classification: Obstructive (non-communicating) hydrocephalus: CSF flow is blocked within the ventricular system before reaching the arachnoid granulations. Ventricular enlargement occurs proximal to the obstruction. Communicating (non-obstructive) hydrocephalus: Ventricular pathways remain patent, but CSF absorption at the arachnoid villi is impaired. CSF overproduction: Rare; occurs mainly in choroid plexus tumors. Absorption is usually partially compensatory unless flow is obstructed. B. Etiologic Classification Congenital Acquired Post-infectious Post-hemorrhagic Neoplastic Vascular Genetic (e.g., X-linked hydrocephalus) C. Pressure-Based Classification Normal-pressure hydrocephalus Hydrocephalus ex vacuo Long-standing overt ventriculomegaly in adults (LOVA) D. Morphologic (Radiologic) Classification Univentricular enlargement (e.g. entrapped 4th ventricle) Biventricular enlargement (e.g. obstruction at foramen of monro) Triventricular hydrocephalus (e.g. aqueductal stenosis) Communicating ventriculomegaly (secondary to IVH or meningitis, e.t.c.) Entrapped fourth ventricle Q. What are the etiologies of hydrocephalus? A. Congenital Causes Chiari II malformation with myelomeningocele Chiari I malformation Primary congenital aqueductal stenosis Secondary aqueductal gliosis from intrauterine events Dandy–Walker malformation (atresia of Magendie and Luschka) X-linked hydrocephalus (L1CAM mutation) Encephaloceles Other developmental anomalies affecting posterior fossa CSF pathways or foraminal patency B. Acquired Causes Infectious: bacterial meningitis, TB meningitis, cysticercosis Hemorrhagic: intraventricular hemorrhage (IVH), subarachnoid hemorrhage (SAH) Neoplastic: tumors obstructing CSF flow (colloid cyst, medulloblastoma, ependymoma, suprasellar tumors) Postoperative: especially after posterior fossa tumor excision or intraventricular surgery Traumatic: post-traumatic SAH or IVH; scarring of subarachnoid pathways Neurosarcoidosis: granulomatous obstruction of CSF pathways C. Vascular Causes Arteriovenous malformations Vein of Galen aneurysmal malformation (VGAM) D. Functional/Physiological Causes Constitutional or benign ventriculomegaly Arrested or compensated hydrocephalus (non-progressive) Q. What are the special forms of hydrocephalus? Special variants include: Hydrocephalus ex vacuo LOVA (long-standing overt ventriculomegaly in adults) External hydrocephalus (benign external hydrocephalus) Entrapped fourth ventricle Arrested hydrocephalus Triventricular hydrocephalus Normal-pressure hydrocephalus Q. What are the clinical features of hydrocephalus in older children and adults? Older children and adults typically present with signs attributable to increased intracranial pressure and disruption of periventricular white matter tracts. Headache Nausea and vomiting Papilledema Impaired concentration and cognitive slowing Gait instability Parinaud’s syndrome from tectal pressure Sixth nerve palsy from elevated ICP Personality changes or irritability Urinary incontinence (late) Blurred vision and visual field defects from chronic papilledema Slow ventricular enlargement may present subtly, with cognitive and gait changes preceding overt ICP symptoms. Q. What are the clinical features of hydrocephalus in infants and young children? Symptoms include: Irritability Excessive crying Poor head control Feeding difficulties Vomiting Failure to thrive Developmental delay Signs include: Progressive macrocephaly with OFC crossing percentiles Bulging or tense anterior fontanelle Prominent scalp veins from reversed venous flow Frontal bossing McEwan’s sign: cracked-pot percussion note Setting sun sign: downward deviation of eyes from pressure on suprapineal recess Hyperreflexia Irregular respirations or apneic spells Sutural diastasis in chronic cases Q. How do you measure OFC and what findings suggest hydrocephalus? Technique: Place a non-stretchable measuring tape over the supraorbital ridge anteriorly and around the most prominent point of the occiput posteriorly. Ensure the tape is snug and hair is flattened. Repeat twice; if measurements differ by more than 2 mm, take a third and average the closest two. Abnormal Findings: OFC growth exceeding 1.25 cm per week OFC above 2 SD for age Head circumference rising across percentile curves Persistent macrocephaly relative to overall growth pattern OFC out of proportion to facial/cranial growth Q. What are the radiologic features of hydrocephalus? The radiologic features can be divided into: A. Acute Hydrocephalus: Reflects sudden obstruction or acute failure of CSF resorption. 1. Temporal horn enlargement ≥ 2 mm Earliest and most sensitive sign. Normally TH is barely visible. Criteria for acute hydrocephalus: TH ≥ 2 mm and fissures/sulci not visible OR TH ≥ 2 mm + FH/ID > 0.5 (not Evans index) 2. Ballooning of frontal horns: “Mickey Mouse” ventricles 3. Widening of the third ventricle: Should normally be slit-like 4. Periventricular low density on CT: Represents transependymal interstitial edema due to stasis of flow around ventricles 5. Periventricular T2 hyperintensity on MRI: Represents CSF stasis rather than actual CSF diffusion through ependyma. 6. Obstructive patterns: Dilated ventricles proximal to the block, for e.g. colloid cyst can cause biventricular enlargement 7. Loss of cortical sulci and cisterns (effacement): Due to acute rise in ICP 8. Upward bowing of corpus callosum from ventricular expansion B. Chronic Hydrocephalus – Radiologic Features Chronic hydrocephalus produces characteristic long-standing changes due to sustained ventricular expansion and cranial remodeling: Beaten copper or beaten silver cranium on skull radiographs Third ventricular downward ballooning into the sella Erosion or empty sella from chronic pressure Temporal horns less prominent than in acute states Macrocrania (>98th percentile OFC) Corpus callosum thinning and upward bowing Widened sutures, delayed closure of fontanelles (infants) Cortical mantle thinning from longstanding ventricular expansion Smooth, rounded ventricular contours Often lack of acute transependymal edema Q. What is the Evans Index and how is it interpreted? Evans Index is the ratio of the maximal frontal horn width divided by the maximal biparietal diameter on the same axial CT or MRI slice. Evans Index >0.3 is considered indicating hydrocephalus. Evans Index <0.3 is usually normal (0.25 is considered a grey zone). Q. What are the limitations of the Evans Index? Evans Index is widely used but has several important limitations: The measurement varies with axial slice angle. Maximal biparietal diameter may not lie on the same slice as maximal frontal horn width. Underestimates pediatric hydrocephalus because occipital horns often enlarge more than frontal horns. Variability in the ratio may exceed actual structural differences. Thus, Evans Index alone should never be used as a sole diagnostic criterion. Q. What is McEwan’s sign? McEwan’s sign is a cracked-pot percussion sound produced when tapping the skull of an infant (mostly at anterior fontanelle) with marked hydrocephalus. It is caused by: Separation of sutures Thinning of cranial bones Increased resonance due to enlarged ventricles It is a classic sign of chronic infantile hydrocephalus. Q. What is external hydrocephalus, and how do you differentiate it from true hydrocephalus? External hydrocephalus, also known as benign external hydrocephalus (BESS), is a condition in which CSF accumulates in the subarachnoid spaces, predominantly over the frontal and frontoparietal convexities, due to delayed maturation of arachnoid villi. It is not obstructive or communicating hydrocephalus, and the ventricles maintain normal or only mildly increased diameter. Pathophysiology: Arachnoid granulations are immature in early infancy. CSF production is normal but absorption is temporarily reduced, thus CSF preferentially expands subarachnoid spaces instead of ventricles. As arachnoid villi mature (by 18–24 months), spaces normalize. Clinical Features: Occurs between 3 and 18 months of age. Macrocephaly with OFC typically above the 97th percentile. Development is normal or near normal. No symptoms of raised intracranial pressure. Positive family history of macrocephaly in some cases. Radiologic Features Enlarged frontal subarachnoid spaces, symmetrical. Interhemispheric fissure widened. Ventricles normal or minimally enlarged, not disproportionate. Cortical mantle thickness normal, which is a major point of differentiation. Cortical vein sign: visible cortical veins crossing the widened subarachnoid spaces, helping differentiate from subdural effusion. Differentiation from True Hydrocephalus External hydrocephalus: Subarachnoid enlargement > ventricular enlargement Normal cortex thickness No sulcal effacement Normal intracranial pressure No transependymal edema Stable OFC growth pattern Resolves spontaneously True hydrocephalus: Ventricular dilation > subarachnoid space dilation Sulcal effacement Periventricular edema Signs of raised ICP Progressive symptoms Requires CSF diversion Course and Prognosis Peaks around 6–12 months Resolves spontaneously by age 2 No long-term neurological deficit expected Management: Observation only Serial OFC and developmental monitoring No role for surgical intervention Imaging only if symptoms change Q. What is arrested hydrocephalus? Arrested hydrocephalus refers to a non-progressive, compensated form of ventriculomegaly in which CSF dynamics reach a steady state. The ventricles are enlarged, but CSF pressure is stable, and the patient has no clinical or radiologic evidence of progression. Pathophysiology: Initial hydrocephalus (congenital, post-infectious, post-hemorrhagic) occurs. CSF absorption pathways partially or completely recover. Ventricular enlargement remains but does not progress. Brain adapts via decreased CSF production, enhanced alternative absorption, and tissue compliance adjustments. Clinical Features: Asymptomatic or minimally symptomatic Normal OFC trajectory in infants No vomiting, irritability, papilledema, or headache Mild developmental delays may persist from initial insult, but no ongoing decline No gait instability or cognitive worsening in older children Radiologic Features Stable ventricular size on sequential CT/MRI No transependymal edema Normal periventricular signal Stable corpus callosum morphology No progressive skull changes In infants: fontanelle and sutures may have adapted and remain static Diagnosis: Requires three components. Clinical stability Radiological stability on serial imaging Absence of raised ICP features Triggers for Reactivation Even stable hydrocephalus can “reactivate”: Meningitis Trauma (sometimes even mild) New hemorrhage Pubertal brain growth Sudden changes in CSF absorption Management: Observation only if fully compensated Serial OFC in infants Neurological and developmental monitoring Imaging every 6–12 months initially Intervention only if reactivation occurs Treatment of Reactivation: ETV if obstructive pattern develops VP shunt if communicating or absorption failure recurs Arrested hydrocephalus should never be shunted unless clearly decompensating, as unnecessary shunting may precipitate subdural hematomas and overdrainage-related complications. Q. What is an entrapped fourth ventricle? Entrapped fourth ventricle is a condition where the fourth ventricle becomes isolated due to obstruction of both its inlet (aqueduct) and outlets (foramina of Magendie and Luschka), leading to progressive dilation of the fourth ventricle and compression of the brainstem and cerebellum. Pathophysiology: Two simultaneous blocks: 1. Aqueductal obstruction: Prevents CSF flow from third to fourth ventricle. Often secondary to gliosis, hemorrhage, or infection. 2. Outlet obstruction Scarring of Magendie/Luschka caused by meningitis, arachnoiditis, or postoperative scarring. CSF continues to be produced by the choroid plexus inside the fourth ventricle, causing a closed compartment with progressive dilation. Etiology: Post-intraventricular hemorrhage Post-meningitic or TB meningitis scarring Postoperative scarring after posterior fossa surgery Aqueductal gliosis Arachnoiditis VP shunting of supratentorial ventricles, leading to collapse above and pressure buildup below Clinical Features: Symptoms are due to brainstem and cerebellar compression: Ataxia and truncal imbalance Dysarthria and dysphagia Horizontal or vertical gaze palsies Nystagmus Irritability or lethargy in infants Respiratory irregularity or apneic spells New neurological deficits after VP shunt insertion (classic presentation) Head circumference may be normal if supratentorial ventricles are decompressed by a shunt Radiological Features: Isolated dilation of the fourth ventricle Supratentorial ventricles normal or small (post-shunting) Fourth ventricle ballooned posteriorly and inferiorly Brainstem flattened and compressed anteriorly Vermis displaced posteriorly Sagittal MRI best demonstrates outlet and aqueductal obstruction No transependymal edema unless chronic Management Options: 1. Endoscopic Aqueductoplasty Removes glial scar tissue from aqueduct. Balloon dilation performed after perforation. Useful when aqueduct obstruction is the primary problem. 2. Aqueductal Stenting Prevents restenosis of newly opened aqueduct. Required in cases of thick gliosis or scarring. Provides long-lasting patency. 3. Fourth Ventricular Shunting Fourth ventriculoperitoneal shunt Fourth ventriculopleural shunt Indicated when outlet obstruction is absolute or endoscopy is not feasible. Access via midline suboccipital route or transforaminal approach. 4. Endoscopic Third Ventriculostomy (ETV) Useful only if aqueduct is obstructed but outlets are patent after surgical restoration. Provides shunt-free diversion of CSF through the third ventricular floor. 5. Posterior Fossa Surgery: Rarely used and reserved for dense arachnoiditis not amenable to endoscopy or shunting. Follow-up: MRI to confirm reduction in fourth ventricular size Neurological monitoring Shunt surveillance if implanted Q. What is X-linked hydrocephalus? X-linked hydrocephalus is a genetic, congenital, severe obstructive hydrocephalus caused by L1CAM gene mutations on the X chromosome. It is inherited in an X-linked recessive pattern, primarily affecting males. Genetic Basis L1CAM encodes an adhesion molecule critical for neuron migration and axon pathfinding. Mutations lead to: Defective neuronal migration Abnormal axonal guidance Midline structural abnormalities Aqueductal stenosis development Structural Abnormalities: Aqueductal stenosis (congenital or acquired from gliosis) Corpus callosum agenesis or hypoplasia Hydrocephalus with massive ventriculomegaly Corticospinal tract malformations Optic nerve hypoplasia in some cases Periventricular heterotopias may occur Clinical Features: Severe hydrocephalus detected antenatally or at birth Macrocephaly Adducted thumbs (classic hallmark of L1 syndrome) Spasticity Developmental delay Seizures may occur Feeding difficulties Variable cognitive impairment depending on structural severity Radiologic Features: Marked triventricular obstructive hydrocephalus Narrowed or absent aqueduct Enlarged lateral and third ventricles Thin cortical mantle if severe Corpus callosum agenesis or hypoplasia Midbrain structural deformities Possible periventricular leukomalacia from chronic stretch Diagnosis: MRI brain Genetic testing confirming L1CAM mutation Family history analysis Management: 1. Ventriculoperitoneal (VP) Shunt: Mainstay of treatment. Required early in life to prevent brain injury 2. ETV: Often has low success because of: Concomitant cisternal abnormalities Poor subarachnoid compliance Complex aqueductal malformations 3. Supportive Management: Physiotherapy for spasticity, seizure management, and developmental therapies Prognosis: Depends on severity of structural abnormalities, timing of intervention, and presence of associated neurological deficits. Q. What are the complications of untreated hydrocephalus? Neurological Complications: Developmental delay Cognitive impairment Learning difficulties Behavioral deterioration Motor dysfunction (spasticity, hemiparesis, gait abnormalities) Visual impairment due to chronic papilledema Seizures Structural Complications Severe macrocephaly (infants) Skull deformities Cortical thinning and permanent loss of cortical mantle Herniation syndromes in acute obstructive hydrocephalus Systemic Complications: Feeding difficulties Respiratory instability Apneic spells End-stage: cardiorespiratory arrest Untreated hydrocephalus leads to permanent brain injury and is fatal. Q. How do you manage hydrocephalus? A. Temporizing Measures External Ventricular Drain (EVD): Immediate CSF diversion in acute obstructive hydrocephalus (IVH, SAH, tumors, postoperative). Used to stabilize ICP before definitive management. B. Definitive Surgical Procedures 1. Ventriculoperitoneal (VP) Shunt Most common definitive treatment Indications: communicating hydrocephalus, post-infectious hydrocephalus, post-hemorrhagic hydrocephalus, failed ETV, NPH Programmable valves used to reduce overdrainage risks 2. Endoscopic Third Ventriculostomy (ETV) Now taken as First-line for obstructive hydrocephalus Indications: congenital aqueductal stenosis, triventricular obstruction, Chiari-related hydrocephalus Avoids shunt dependence Success dependent on age, etiology, cisternal anatomy 3. ETV with Choroid Plexus Cauterization (ETVCPC) Effective in infants Increases ETV success by reducing CSF production Especially beneficial in spina bifida and complex obstructive etiologies 4. Fourth Ventricular Shunting Indicated for entrapped fourth ventricle Options: VP or VPL shunts with catheter positioned into the fourth ventricle 5. Lumboperitoneal Shunt Used in communicating hydrocephalus with small ventricles Useful in NPH when ventricles are not dilated enough for ventricular catheter placement C. Principles of Management Treat underlying cause (e.g., tumor, infection) Avoid rapid decompression after SAH/IVH to prevent rebleeding Ensure sterile technique to prevent shunt infections Careful valve selection and postoperative monitoring D. Postoperative Follow-up Shunt patency assessment Serial imaging Monitoring for overdrainage (subdural hematoma), underdrainage, infection Neurodevelopmental assessment in children Regular ETV success evaluation (ETVSS considerations)

Coming Soon.

TNCR RAPID REVIEW Please note that these review notes were primarily developed on the pattern of Exit Exams for FCPS and MS Neurosurgery. They are not a replacement for textbooks, but a brilliant way for last minute revision. Congenital Cranial Tumors & Tumor-like Lesions Vascular Infections Spine Spinal Tumors Trauma Miscellaneous

Pilocytic Astrocytoma | Imaging, Unusual Presentations & Core Concepts The session begins with a concise overview of pilocytic astrocytoma, followed by a detailed discussion of classic and atypical imaging appearances, including patterns that can lead to diagnostic confusion. Emphasis is placed on correlating imaging findings with tumor biology, age, and location, helping trainees avoid common pitfalls in interpretation.

Lipomyelomeningocele A lipomyelomeningocele is a closed, skin-covered spinal dysraphism in which a subcutaneous lipoma extends through a bony defect and intermingles with the neural placode, causing tethering of the spinal cord. The neural placode–lipoma interface lies outside the spinal canal because the dura is expanded into a sac-like configuration. Q. How does lipomyelomeningocele differ from lipomyelocele? The key difference lies in the position of the placode-lipoma interface: In lipomyelomeningocele, the placode–lipoma junction lies outside the spinal canal, and the dura forms a meningocele-like expansion. In lipomyelocele, the placode–lipoma interface remains within the spinal canal, and the dorsal defect is smaller with no significant dural expansion. Both represent premature dysjunction with mesenchymal invasion, but lipomyelomeningocele is anatomically more externalized. Q. What is the embryological basis of lipomyelomeningocele? It arises from premature dysjunction i.e. the surface ectoderm separates from neural ectoderm too early during primary neurulation. This allows mesenchymal fat cells to invade the open neural plate, becoming incorporated into the forming spinal cord. As the cord closes, the fat remains attached, creating a tethering lipoma that extends out through a bony defect. Q. How does a child with lipomyelomeningocele typically present? Most children present with a skin-covered subcutaneous mass in the lumbosacral area, often with associated cutaneous markers such as a fatty lump, skin discoloration, or asymmetric gluteal cleft. Neurological deficits may be absent initially, but progressive tethered cord symptoms develop with growth, including gait disturbance, lower limb weakness, foot deformities, scoliosis, back pain, and urological deterioration such as neurogenic bladder. Dermal sinus tracts or infection may occur if associated epithelial elements are present. Q. What imaging features suggest lipomyelomeningocele? MRI is diagnostic. It shows: A subcutaneous fat mass entering the spinal canal. A thickened filum or lipoma attached to the neural placode. The placode–lipoma interface located outside (in LMM) or inside (in LMC) the spinal canal. Low-lying conus, usually below L2–L3. Expanded dorsal dura in lipomyelomeningocele. CT may show a posterior bony defect. MRI also evaluates associated tethered cord, syringomyelia, or split cord malformation. Q. What are the indications for surgery in lipomyelomeningocele? Surgery is indicated in: Progressive neurological deficits Urological deterioration on urodynamics Orthopedic changes such as cavovarus foot or scoliosis Documented tethered cord Symptomatic or enlarging lipoma Some surgeons also advocate prophylactic early surgery due to progressive tethering expected with growth, although timing varies by center. Q. How will you surgically repair a lipomyelomeningocele? I will position the child prone and mark the midline carefully. After sterile preparation, I will perform a midline skin incision over the subcutaneous lipoma and reflect the skin flaps to expose the fatty mass. I will dissect the lipoma circumferentially, identifying its deep extension into the spinal canal through the bony defect. Using the microscope, I will remove surrounding fat until I clearly identify the lipoma–placode interface. I will perform a laminotomy around the defect as needed to expose the dura. I will open the dura longitudinally and tack it laterally. I will then identify the neural placode and inspect its attachment to the lipoma. I will use sharp microsurgical dissection to separate the lipoma from the neural tissue, preserving all functional nerve roots. I will follow the lipoma cranially and caudally until the tethering component is released. I will debulk the lipoma internal to the canal while avoiding traction on neural structures. Once I free the placode from the lipoma, I will reconstruct the neural placode by approximating its medial edges. I will perform a generous dural expansion (duraplasty) using autologous or synthetic graft material to create a capacious dural sac that prevents retethering. I will achieve meticulous hemostasis and close the dura in a watertight manner. Finally, I will close muscle, fascia, subcutaneous tissue, and skin in layered fashion to provide robust coverage. Q. What perioperative complications can occur during surgery for lipomyelomeningocele? Perioperative complications include injury to the neural placode or exiting nerve roots during lipoma–placode dissection, leading to new motor or sensory deficits. Excessive bleeding from epidural veins or the lipoma can obscure the field. Dural tears outside the planned opening can make watertight closure difficult and predispose to CSF leak. Inadequate duraplasty or failure to create a capacious dural sac can leave the cord under tension and risk early retethering. Anesthetic issues in the prone position, hypothermia in small children, and hemodynamic instability can also complicate the procedure. Q. What postoperative complications may follow lipomyelomeningocele repair? Postoperative complications include CSF leak, pseudomeningocele, wound dehiscence, and wound infection or meningitis. New or worsened neurological deficits may appear if roots or cord have been injured or compressed. There is a significant long-term risk of retethering due to scarring at the placode–dural interface, which may present with recurrent pain, new weakness, foot deformity, or bladder deterioration. Progressive spinal deformity, particularly scoliosis or lordosis, can develop with growth. Urological complications may persist or worsen despite adequate detethering, requiring ongoing urology follow-up. Q. How will you counsel the parents of a child with lipomyelomeningocele pre-operatively? I will explain that lipomyelomeningocele is a congenital fatty mass attached to the spinal cord, causing tethering that can worsen with growth. I will clarify that the aim of surgery is to release the tethering, separate the lipoma from the neural tissue as safely as possible, and expand the dura to reduce the risk of future tethering. I will emphasize that surgery is intended primarily to stabilize or slow progression, not to guarantee neurological improvement, and that pre-existing deficits, especially bladder dysfunction, may not fully recover. I will discuss perioperative risks including CSF leak, infection, and possible new weakness or sensory changes. I will stress the need for long-term follow-up with neurosurgery, urology, and orthopedics, warn about the possibility of retethering and further surgery in the future, and address their questions about walking potential, schooling, and continence in realistic but reassuring terms. Q. What is the prognosis of lipomyelomeningocele? Prognosis depends on preoperative neurological status. Early surgery offers better stabilization of motor and bladder function, but lifelong risk of retethering remains. Most children require long-term orthopedic and urological follow-up. Outcomes are generally better when surgery is performed before neurological decline. Q. Are there any recent advancements in the management of lipomyelomeningocele? Recent advancements focus on safer detethering and better long-term control of retethering. Intraoperative neurophysiological monitoring of motor and sensory pathways helps distinguish functional neural tissue from lipoma during dissection, reducing the risk of new deficits. High-resolution MRI and careful preoperative mapping improve understanding of the placode–lipoma interface. Modern duraplasty materials and techniques aim to create a generous, non-constricting dural sac to delay or reduce retethering. There is also increasing emphasis on early MRI-based screening, structured urodynamic follow-up, and multidisciplinary management protocols integrating neurosurgery, urology, and orthopedics to preserve function over time.

Spinal Dysraphism Q. What do you mean by spinal dysraphism? Spinal dysraphism refers to a spectrum of congenital defects arising from abnormal closure, development, or separation of the neural tube and its surrounding mesenchymal structures. It includes open dysraphism (neural tissue exposed due to failed primary neurulation, e.g., myelomeningocele, myeloschisis) and closed dysraphism (skin-covered lesions resulting from disordered neurulation or mesenchymal differentiation, e.g., lipomyelomeningocele, dermal sinus tract, diastematomyelia). Q. How do you classify spinal dysraphism? Spinal dysraphism is broadly classified into: Open spinal dysraphism (not covered with skin): These result from failed primary neurulation and include: Myelomeningocele Myeloschisis Closed spinal dysraphism (skin-covered): These arise from defective disjunction or disordered mesenchymal development and include: Lipomyelomeningocele Lipomyelocele Dermal sinus tract Neurenteric cyst Diastematomyelia (split cord malformation) Fatty filum/Thick filum Terminal myelocystocele Complex dysraphic syndromes: Currarino triad OEIS complex Caudal regression syndromes Q. How does normal neurulation occur? Neurulation proceeds in two phases: Primary neurulation (third to fourth week): Neural plate folds and fuses to form the neural tube from cervical to upper sacral levels. This process requires coordinated bending, elevation, fusion, and separation of neural ectoderm from non-neural ectoderm. Secondary neurulation (caudal cell mass): Mesenchymal cells condense, canalize, and fuse with the distal neural tube to form the conus and filum terminale. Normal neurulation ends with dysjunction, the separation of neural ectoderm from surface ectoderm, allowing mesenchymal elements to migrate and form vertebral tissues. Q. What are the embryological mechanisms leading to spinal dysraphism? The embryological defects include: Failure of neural tube closure causes open dysraphism such as myelomeningocele or myeloschisis. Premature dysjunction causes mesenchymal invasion into neural folds and leads to lipomyelomeningocele. Failure of dysjunction causes a persistent tract connecting skin and neural tube (dermal sinus). Failure of secondary neurulation causes terminal myelocystocele, caudal regression, tight filum. Midline mesenchymal cleavage anomalies cause diastematomyelia (split cord conditions). Persistent neurenteric canal or endodermal misplacement causes neurenteric cysts. Abnormal notochord formation or splitting causes associated vertebral segmentation defects. The type of dysraphism depends on the timing and level of neurulation failure. Q. What are the pathological differences between open and closed dysraphism? In open dysraphism, neural tissue is externally exposed. The neural placode is continuous with skin edges and lacks meningeal or skin covering. These lesions inevitably involve Chiari II malformation, hydrocephalus, and brainstem abnormalities. In closed dysraphism, the defect is covered by skin and neural elements are contained within the spinal canal. These lesions are more variable; some symptomatic at birth but others present later due to tethering, dermal sinus infection, or inclusion tumors. Q. What is the epidemiology of spinal dysraphism? The global incidence is approximately 1–3 per 1000 live births, with higher rates reported in regions with nutritional deficiencies, including parts of Asia. Myelomeningocele is the most common form. Females are more commonly affected in open dysraphism. Q. What are the major risk factors for spinal dysraphism? Important risk factors include: Maternal folic acid deficiency (most significant modifiable risk factor) Maternal diabetes Hyperthermia during early pregnancy Teratogenic drugs (especially valproate and carbamazepine) Genetic predisposition and consanguinity Intrauterine infections and environmental toxins Adequate folate supplementation reduces the risk by nearly 70%. Q. How does spinal dysraphism present clinically? Presentation depends on subtype. Open dysraphism presents at birth with an exposed neural placode. Motor deficits, sensory loss, and bladder dysfunction are present from birth. Closed dysraphism may be detected by cutaneous markers such as: Hairy tuft Dermal pit or sinus Hemangioma Subcutaneous lipoma Skin tag Asymmetric gluteal cleft Neurological symptoms include: Foot deformities Progressive scoliosis Back pain Lower limb weakness Sensory loss Urological presentation includes neurogenic bladder, urgency, retention, and recurrent UTIs. Dermal sinus tract may present with meningitis or dermoid abscess. Split cord malformation may present with scoliosis, foot deformity, or tethered cord. Q. Which associated anomalies are commonly seen with spinal dysraphism? Chiari II malformation (universal in open dysraphism) Hydrocephalus Syringomyelia Orthopedic deformities (clubfoot, hip dislocation) Neurogenic bladder and bowel dysfunction Vertebral anomalies (hemivertebra, butterfly vertebra) Presacral masses in Currarino syndrome Q. How do you investigate a child with suspected spinal dysraphism? MRI spine is the investigation of choice; it identifies neural placode, fat infiltration, split cord anomalies, dermal sinus tracts, and tethering. MRI brain to assess Chiari II and hydrocephalus in open dysraphism. Ultrasound spine for neonates with skin markers (before ossification). CT spine for bony anomalies such as diastematomyelia spur. Urodynamic studies in all dysraphism patients at baseline. Renal ultrasound for hydronephrosis due to neurogenic bladder. Q. What are the general principles of managing spinal dysraphism? Management is tailored to subtype but general rules include: Open dysraphism requires urgent surgical closure within 24–48 hours to reduce infection risk and protect neural tissue. Hydrocephalus evaluation and treatment (VP shunt or ETV) is integral. Closed dysraphism is managed based on symptoms or high-risk features: Progressive motor or bladder symptoms Dermal sinus tract (absolute indication due to meningitis risk) Lipomyelomeningocele with tethering Split cord malformation with spur Multidisciplinary approach with neurosurgery, urology, orthopedics, rehabilitation. Long-term follow-up for re-tethering, scoliosis, and urological decline. Q. What are the long-term complications of spinal dysraphism? Progressive tethered cord due to growth Re-tethering after surgery Hydrocephalus requiring shunt revisions Inclusion tumors (dermoid/epidermoid) Orthopedic deformities Chronic urological dysfunction leading to renal damage Chronic pain and gait abnormalities Q. What is the prognosis? Prognosis depends on the subtype and timing of intervention. Open dysraphism has lifelong neurological and urological morbidity, although early repair improves outcomes. Closed dysraphism has a more favorable prognosis if detected early and treated before neurological decline. Regular monitoring for re-tethering and bladder deterioration is essential. Q. What is the Currarino triad? Currarino triad is a congenital caudal dysraphism defined by the classic triad of anorectal malformation, hemisacrum (sacral defect), and a presacral mass such as an anterior meningocele, teratoma, or enteric cyst, resulting from abnormal development of the caudal eminence and notochord. Q. What is the OEIS complex? The OEIS complex is a severe midline developmental disorder characterized by Omphalocele, Exstrophy of the cloaca, Imperforate anus, and Spinal defects, representing one of the most severe forms of caudal dysraphism. Q. What is caudal regression syndrome? Caudal regression syndrome is a spectrum of secondary neurulation defects involving variable degrees of sacral agenesis, lumbar vertebral anomalies, and spinal cord dysgenesis, commonly associated with maternal diabetes and presenting with lower-limb, urological, and anorectal abnormalities.